Linvoseltamab-Carfilzomib Yields High Complete Response Rate in Multiple Myeloma

By News Health
2 months Ago

(MedPage Today) — In updated results from the LINKER-MM2 trial presented at the recent American Society of Clinical Oncology meeting, the combination of linvoseltamab (Lynozyfic) and carfilzomib (Kyprolis) produced deep, durable responses in patients…

Source link : https://www.medpagetoday.com/meetingcoverage/ascovideopearlsmm/116387

Author :

Publish date : 2025-07-07 16:33:00

Copyright for syndicated content belongs to the linked Source.

Categories: Health News

Related Content

Texas Bill Would Let Residents Sue Out-of-State Abortion Pill Providers

Baby dies of whooping cough after mother not vaccinated while pregnant

County Durham mother's vaccination plea after 'terrifying' measles

Doctors Dismissed Her Symptoms for Years Before Lyme Disease Diagnosis

Remote ECG Screening Ups AF Detection ‘Modestly’

Year of Low-Dose DOAC Slashes Recurrence After Provoked VTE